Skip to main content

Davern Capital Partners, LP

13F filer · CIK 0002003147
Reported Aug 13, 2026
Net buyer this quarter
13F portfolio value$587MU.S. long equity reported on 13F
Positions153 new · 5 closed
Net flow last quarter+$189MBuys minus sells
Top 10 positions weight86.8%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 13, 202615 positions
BNTXBioNTech SE$70.2M11.97%0.30%+147.4%Q4 2025
ROIVRoivant Sciences Ltd.$68.4M11.66%0.27%+121.3%Q4 2025
RPRXRoyalty Pharma plc$64.8M11.05%0.30%+122.3%Q4 2025
IONSIonis Pharmaceuticals Inc$63.3M10.80%0.48%+106.4%Q4 2025
INSMINSMED Inc$59.7M10.18%0.26%+206.7%Q1 2026
REGNRegeneron Pharmaceuticals, Inc.$57.8M9.85%0.10%+106.8%Q4 2025
LEGNLegend Biotech Corp$34.4M5.87%0.32%-9.4%Q4 2025
ALNYAlnylam Pharmaceuticals, Inc.$34M5.80%0.08%NewQ2 2026
NTRANatera, Inc.$32.3M5.51%0.08%-17.4%Q4 2025
GPCRStructure Therapeutics Inc.$23.9M4.08%0.21%+252.7%Q1 2026
MLYSMineralys Therapeutics, Inc.$23.2M3.95%0.97%+92.1%Q4 2025
VERAVera Therapeutics, Inc.$21.4M3.65%0.69%NewQ2 2026
GENBGenerate Biomedicines, Inc.$13.9M2.37%0.64%+39.4%Q1 2026
PRCTPROCEPT BioRobotics Corp$10.5M1.79%0.81%+78.0%Q1 2026
AVTXAvalo Therapeutics, Inc.$8.66M1.48%0.89%NewQ2 2026
Q1 2026Reported May 14, 202617 positions
PFEPfizer Inc$44.8M12.28%0.03%-22.0%Q4 2025
REGNRegeneron Pharmaceuticals, Inc.$34.6M9.50%0.05%-14.5%Q4 2025
INSMINSMED Inc$29.9M8.19%0.08%NewQ1 2026
IONSIonis Pharmaceuticals Inc$29.1M7.97%0.23%+62.2%Q4 2025
NTRANatera, Inc.$28.8M7.90%0.10%+83.1%Q4 2025
BNTXBioNTech SE$27.1M7.44%0.12%-17.8%Q4 2025
ARGXArgenx SE$25.6M7.02%0.06%-1.8%Q4 2025
LLYELI LILLY & Co$25.1M6.88%0.00%+228.4%Q4 2025
RPRXRoyalty Pharma plc$24.9M6.84%0.13%-38.1%Q4 2025
ROIVRoivant Sciences Ltd.$24.2M6.64%0.12%-15.1%Q4 2025
LEGNLegend Biotech Corp$23.8M6.52%0.36%+24.4%Q4 2025
MLYSMineralys Therapeutics, Inc.$12.1M3.32%0.54%+112.3%Q4 2025
ABVXAbivax S.A.$8.7M2.39%0.10%+61.1%Q4 2025
GENBGenerate Biomedicines, Inc.$7.4M2.03%0.46%NewQ1 2026
PRCTPROCEPT BioRobotics Corp$6.53M1.79%0.46%NewQ1 2026
GPCRStructure Therapeutics Inc.$6.1M1.67%0.06%NewQ1 2026
VRDNViridian Therapeutics, Inc.\DE$5.92M1.62%0.30%+15.6%Q4 2025
Q4 2025Reported Feb 13, 202614 positions
PFEPfizer Inc$50.9M16.44%0.04%NewQ4 2025
REGNRegeneron Pharmaceuticals, Inc.$40.5M13.08%0.06%NewQ4 2025
BNTXBioNTech SE$35.3M11.43%0.15%NewQ4 2025
RPRXRoyalty Pharma plc$32.5M10.50%0.22%NewQ4 2025
ARGXArgenx SE$30M9.70%0.06%NewQ4 2025
LEGNLegend Biotech Corp$23M7.43%0.29%NewQ4 2025
ROIVRoivant Sciences Ltd.$22.3M7.21%0.14%NewQ4 2025
IONSIonis Pharmaceuticals Inc$18.9M6.10%0.15%NewQ4 2025
NTRANatera, Inc.$18M5.83%0.06%NewQ4 2025
LLYELI LILLY & Co$8.93M2.89%0.00%NewQ4 2025
VRDNViridian Therapeutics, Inc.\DE$8.14M2.63%0.26%NewQ4 2025
MLYSMineralys Therapeutics, Inc.$7.64M2.47%0.26%NewQ4 2025
CGONCG Oncology, Inc.$6.73M2.17%0.20%NewQ4 2025
ABVXAbivax S.A.$6.54M2.11%0.06%NewQ4 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.